Tags

Type your tag names separated by a space and hit enter

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
Eur Respir J. 2020 06; 55(6)ER

Abstract

The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.

Authors+Show Affiliations

Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile mkhoury@uandes.cl. Cells for Cells and consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile. M. Khoury and D.J. Weiss contributed equally as lead authors of the study.Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile. Cells for Cells and consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile.Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil.Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile. Cells for Cells and consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile.Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil.Dept of Medicine, University of Vermont, Burlington, VT, USA. M. Khoury and D.J. Weiss contributed equally as lead authors of the study.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32265310

Citation

Khoury, Maroun, et al. "Current Status of Cell-based Therapies for Respiratory Virus Infections: Applicability to COVID-19." The European Respiratory Journal, vol. 55, no. 6, 2020.
Khoury M, Cuenca J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020;55(6).
Khoury, M., Cuenca, J., Cruz, F. F., Figueroa, F. E., Rocco, P. R. M., & Weiss, D. J. (2020). Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. The European Respiratory Journal, 55(6). https://doi.org/10.1183/13993003.00858-2020
Khoury M, et al. Current Status of Cell-based Therapies for Respiratory Virus Infections: Applicability to COVID-19. Eur Respir J. 2020;55(6) PubMed PMID: 32265310.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. AU - Khoury,Maroun, AU - Cuenca,Jimena, AU - Cruz,Fernanda F, AU - Figueroa,Fernando E, AU - Rocco,Patricia R M, AU - Weiss,Daniel J, Y1 - 2020/06/04/ PY - 2020/03/25/received PY - 2020/04/03/accepted PY - 2020/4/9/pubmed PY - 2020/6/13/medline PY - 2020/4/9/entrez JF - The European respiratory journal JO - Eur Respir J VL - 55 IS - 6 N2 - The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations. SN - 1399-3003 UR - https://www.unboundmedicine.com/medline/citation/32265310/Current_status_of_cell_based_therapies_for_respiratory_virus_infections:_applicability_to_COVID_19_ DB - PRIME DP - Unbound Medicine ER -